TAT-11: The Use of Albumin Binders as a Strategy to Optimize Tumor Delivery
Overall survival was also much better: >120 days for Lu177-HTK01169 compared to 58 days for PSMA617 or 14 days for the saline control sample. In the future, they plan to improve kidney uptake by optimization of the albumin binder.
Presented by: Kuo-Shyan Lin, Ph.D., Senior Scientist, Department of Molecular Oncology, and Associate Professor, Radiology, the University of British Columbia, Department of Radiology, Vancouver, British Columbia, Canada
Written by: William Carithers, Lawrence Berkeley National Laboratory at the 11th International Symposium on Targeted Alpha Therapy (TAT-10) April 1 - April 4, 2019 - Ottawa, ON, Canada